197 related articles for article (PubMed ID: 23588203)
81. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27.
Kirmizis A; Bartley SM; Kuzmichev A; Margueron R; Reinberg D; Green R; Farnham PJ
Genes Dev; 2004 Jul; 18(13):1592-605. PubMed ID: 15231737
[TBL] [Abstract][Full Text] [Related]
82. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
[TBL] [Abstract][Full Text] [Related]
83. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
Chen S; Chen J; Zhan Q; Zhu Y; Chen H; Deng X; Hou Z; Shen B; Chen Y; Peng C
Oncotarget; 2014 Nov; 5(21):10421-33. PubMed ID: 25431952
[TBL] [Abstract][Full Text] [Related]
84. The histone H3K27 methylation mark regulates intestinal epithelial cell density-dependent proliferation and the inflammatory response.
Turgeon N; Blais M; Delabre JF; Asselin C
J Cell Biochem; 2013 May; 114(5):1203-15. PubMed ID: 23192652
[TBL] [Abstract][Full Text] [Related]
85. BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
M JR; S V
Gene; 2018 Dec; 678():302-311. PubMed ID: 30096458
[TBL] [Abstract][Full Text] [Related]
86. Polycomb repressive complex 2 inhibitors: emerging epigenetic modulators.
Danishuddin ; Subbarao N; Faheem M; Khan SN
Drug Discov Today; 2019 Jan; 24(1):179-188. PubMed ID: 30031878
[TBL] [Abstract][Full Text] [Related]
87. PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.
Nagarsheth N; Peng D; Kryczek I; Wu K; Li W; Zhao E; Zhao L; Wei S; Frankel T; Vatan L; Szeliga W; Dou Y; Owens S; Marquez V; Tao K; Huang E; Wang G; Zou W
Cancer Res; 2016 Jan; 76(2):275-82. PubMed ID: 26567139
[TBL] [Abstract][Full Text] [Related]
88. Integrative epigenome analysis identifies a Polycomb-targeted differentiation program as a tumor-suppressor event epigenetically inactivated in colorectal cancer.
Tan J; Yang X; Jiang X; Zhou J; Li Z; Lee PL; Li B; Robson P; Yu Q
Cell Death Dis; 2014 Jul; 5(7):e1324. PubMed ID: 25032847
[TBL] [Abstract][Full Text] [Related]
89. Regulation of the expression of claudin 23 by the enhancer of zeste 2 polycomb group protein in colorectal cancer.
Maryan N; Statkiewicz M; Mikula M; Goryca K; Paziewska A; Strzałkowska A; Dabrowska M; Bujko M; Ostrowski J
Mol Med Rep; 2015 Jul; 12(1):728-36. PubMed ID: 25695204
[TBL] [Abstract][Full Text] [Related]
90. 3-Deazaneplanocin A (DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation.
Fujiwara T; Saitoh H; Inoue A; Kobayashi M; Okitsu Y; Katsuoka Y; Fukuhara N; Onishi Y; Ishizawa K; Ichinohasama R; Harigae H
J Biol Chem; 2014 Mar; 289(12):8121-34. PubMed ID: 24492606
[TBL] [Abstract][Full Text] [Related]
91. A small molecule inhibitor of polycomb repressive complex 1 inhibits ubiquitin signaling at DNA double-strand breaks.
Ismail IH; McDonald D; Strickfaden H; Xu Z; Hendzel MJ
J Biol Chem; 2013 Sep; 288(37):26944-54. PubMed ID: 23902761
[TBL] [Abstract][Full Text] [Related]
92. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer.
Sato T; Kaneda A; Tsuji S; Isagawa T; Yamamoto S; Fujita T; Yamanaka R; Tanaka Y; Nukiwa T; Marquez VE; Ishikawa Y; Ichinose M; Aburatani H
Sci Rep; 2013; 3():1911. PubMed ID: 23714854
[TBL] [Abstract][Full Text] [Related]
93. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
[TBL] [Abstract][Full Text] [Related]
94. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
Katona BW; Liu Y; Ma A; Jin J; Hua X
Cancer Biol Ther; 2014; 15(12):1677-87. PubMed ID: 25535899
[TBL] [Abstract][Full Text] [Related]
95. DAZL limits pluripotency, differentiation, and apoptosis in developing primordial germ cells.
Chen HH; Welling M; Bloch DB; Muñoz J; Mientjes E; Chen X; Tramp C; Wu J; Yabuuchi A; Chou YF; Buecker C; Krainer A; Willemsen R; Heck AJ; Geijsen N
Stem Cell Reports; 2014 Nov; 3(5):892-904. PubMed ID: 25418731
[TBL] [Abstract][Full Text] [Related]
96. EZH2-mediated H3K27 trimethylation mediates neurodegeneration in ataxia-telangiectasia.
Li J; Hart RP; Mallimo EM; Swerdel MR; Kusnecov AW; Herrup K
Nat Neurosci; 2013 Dec; 16(12):1745-53. PubMed ID: 24162653
[TBL] [Abstract][Full Text] [Related]
97. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming.
Tiwari N; Tiwari VK; Waldmeier L; Balwierz PJ; Arnold P; Pachkov M; Meyer-Schaller N; Schübeler D; van Nimwegen E; Christofori G
Cancer Cell; 2013 Jun; 23(6):768-83. PubMed ID: 23764001
[TBL] [Abstract][Full Text] [Related]
98. Emerging role of G9a in cancer stemness and promises as a therapeutic target.
Haebe JR; Bergin CJ; Sandouka T; Benoit YD
Oncogenesis; 2021 Nov; 10(11):76. PubMed ID: 34775469
[TBL] [Abstract][Full Text] [Related]
99. Identification of macrophage related gene in colorectal cancer patients and their functional roles.
Chen Y; Zhang C; Zou X; Yu M; Yang B; Ji CF; Gao SY; Li J; Liu B
BMC Med Genomics; 2021 Jun; 14(1):159. PubMed ID: 34120619
[TBL] [Abstract][Full Text] [Related]
100. G9a Is SETting the Stage for Colorectal Oncogenesis.
Bergin CJ; Benoit YD
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32512705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
